Key facts
- Ascilion’s last known valuation is $24.5M (Jan 2022).
- It has raised $8.2M; the latest was PE Growth/Expansion ($2.2M) in Sep 2025.
- Notable investors include Lotus Singapore Group, Nordstjernan.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ascilion
- ·The full record, as it builds
Funding rounds
No funding rounds for Ascilion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ascilion
Manufacturer of syringes intended for the painless extraction of interstitial fluid. The company uses a proprietary array of tiny hollow microneedles for easy-to-use auto extractors along with a set of detachable consumables for safe interstitial fluid collection and handling, enabling clinics for painless health monitoring and disease.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2012
- Employees
- 10
- Website
- ascilion.com/
- Ownership
- Privately Held (backing)
Ascilion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ascilion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ascilion in its N-PORT filings yet. We sweep new filings monthly.